

REGISTERED NUMBER: 04146962 (England and Wales)


Strategic Report, Report of the Director and

Financial Statements

for the Year Ended 30 June 2020

for

Catalent U.K. Swindon Holding II Limited



Catalent U.K. Swindon Holding II Limited (Registered number: 04146962)

Contents of the Financial Statements
for the Year Ended 30 June 2020

	Page
Company Information	1
Strategic Report	2
Report of the Director	3
Report of the Independent Auditors	5
Statement of Comprehensive Income	7
Statement of Financial Position	8
Statement of Changes in Equity	9
Notes to the Financial Statements	10

Catalent U.K. Swindon Holding II Limited (Registered number: 04146962)

Company Information
for the Year Ended 30 June 2020

DIRECTORS:

J Arnold
W Joseph
A Reed

SECRETARY:

A Reed

REGISTERED OFFICE:

Frankland Road
Blagrove
Swindon
Wiltshire
SN5 8YG
United Kingdom

REGISTERED NUMBER:

04146962 (England and Wales)

AUDITORS:

Ernst & Young LLP
The Paragon
Counterslip
Bristol
BS1 6BX

Catalent U.K. Swindon Holding II Limited (Registered number: 04146962)

Strategic Report
for the Year Ended 30 June 2020

The directors present their strategic report for the year ended 30 June 2020.

PRINCIPAL ACTIVITY

The principal activity of the company in the year under review was that of an intermediate holding company.

REVIEW OF BUSINESS

The result for the year after taxation amounted to £nil (2019: £nil).


The directors have considered and reviewed business risks relating to Catalent U.K. Swindon Holding II Limited. As this company is a holding company there are no commercial or regulatory risks. There are also no interest rate or exchange rate risks borne by this entity.

As a holding company, the risks of the entity are limited to the performance of the investments. An investment impairment review is considered annually and it was decided that no impairment was necessary (2019: £nil)."

FUTURE DEVELOPMENTS

The directors have assessed the impact of the COVID-19 pandemic in detail in the Directors' Report.

ON BEHALF OF THE BOARD:

DocuSigned by:

.....532054688D10422.....
A Reed - Director
10-Dec-2020
Date:

Catalent U.K. Swindon Holding II Limited (Registered number: 04146962)

Report of the Directors
for the Year Ended 30 June 2020

The directors present their report with the financial statements of the company for the year ended 30 June 2020.

FUTURE DEVELOPMENTS

There is no anticipated change in the future activity of this entity.

GOING CONCERN

The Company has limited activity and has limited cash flows outside of the Catalent Inc ("Catalent") group. The recoverability of its assets is dependent on the financial position of the Catalent group. The impact of COVID-19 (coronavirus) on global economic development is currently unpredictable, however Catalent has significant liquidity headroom as a result of the continued successful operational performance of the Group.

The directors have viewed the going concern of the business for a period of at least 12 months from the approval date and having assessed the responses of the management of Catalent to their enquiries have no reason to believe that a material uncertainty exists that may cast significant doubt on the ability of the Catalent group to continue as a going concern. On the basis of their assessment of the Company's financial position and relevant enquiries, the directors have a reasonable expectation that the Company will be able to continue in operational existence for the foreseeable future. Thus, they continue to adopt the going concern basis of accounting in preparing the annual financial statements.

DIRECTORS

The directors shown below have held office during the whole of the period from 1 July 2019 to the date of this report.

J Arnold
W Joseph
A Reed

DIRECTORS' INDEMNITY INSURANCE

The company has granted an indemnity to one or more of its directors against liability in respect of proceedings brought by third parties, subject to the conditions set out in section 234 of the Companies Act 2006. Such qualifying third party indemnity provision remains in force as at the date of approving the directors' report.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS

So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and the directors have taken all the steps that they ought to have taken as directors in order to make themselves aware of any relevant audit information and to establish that the company's auditors are aware of that information.

AUDITORS

An elective resolution has been passed to dispense with the obligation to appoint Ernst & Young LLP as auditors on an annual basis.

STATEMENT OF DIRECTOR'S RESPONSIBILITIES

The directors are responsible for preparing the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards, including "Financial Reporting Standard 102 'The Financial Reporting Standard applicable to the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice)".

Catalent U.K. Swindon Holding II Limited (Registered number: 04146962)


Report of the Directors - continued
for the Year Ended 30 June 2019

Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether United Kingdom Generally Accepted Accounting Practice has been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

ON BEHALF OF THE BOARD:

DocuSigned by:
 10-Dec-2020
532054086D1D422.....
A Reed - Director

Independent Auditor's Report to the members of Catalent U.K. Swindon Holding II Limited

Opinion

We have audited the financial statements of Catalent U.K. Swindon Holding II Limited for the year ended 30 June 2020 which comprise of the Statement of Comprehensive Income, the Statement of Changes in Equity, the Statement of Financial Position and the related notes from 1 to 14, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the company's affairs as at 30 June 2020 and of its financial performance for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report below. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of matter - Effects of COVID-19

We draw attention to Note 2 of the financial statements, which describes the economic and social consequences the company is facing as a result of COVID-19 which is impacting the entities ability to continue as a going concern. Our opinion is not modified in respect of this matter.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the directors' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the directors have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The directors are responsible for the other information.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in this report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of the other information, we are required to report that fact.

We have nothing to report in this regard.

Independent Auditor's Report to the members of Catalent U.K. Swindon Holding II Limited

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the strategic report and directors' report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or directors' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the directors' responsibilities statement set out on page 3, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Ernst & Young LLP

Jane Barwell (Senior Statutory Auditor)
for and on behalf of Ernst & Young LLP
Bristol

Date: 15 December 2020

Catalent U.K. Swindon Holding II Limited (Registered number: 04146962)**Statement of Comprehensive Income**
for the Year Ended 30 June 2020

	Notes	2020 £	2019 £
TURNOVER		-	-
OPERATING PROFIT		-	-
Income from investments	6	<u>4,494,854</u>	<u>-</u>
		4,494,854	-
Amounts written off investments	7	<u>(4,494,854)</u>	<u>-</u>
PROFIT ON ORDINARY ACTIVITIES BEFORE TAXATION		-	-
Tax on profit on ordinary activities	8	<u>-</u>	<u>-</u>
PROFIT FOR THE FINANCIAL YEAR		-	-
OTHER COMPREHENSIVE INCOME		-	-
TOTAL COMPREHENSIVE INCOME FOR THE YEAR		<u>-</u>	<u>-</u>

The company does not have any unrecognised profits or losses other than the above.

There is no material difference between the profit on ordinary activities before tax and the profit for the financial year stated above and their historical equivalents.

All amounts relate to continuing activities.

The notes from 1 to 14 form part of these financial statements.

Catalent U.K. Swindon Holding II Limited (Registered number: 04146962)**Statement of Financial Position**
for the Year Ended 30 June 2020

	Notes	2020 £	2019 £
FIXED ASSETS			
Investments	9	1,000,065	5,452,998
CURRENT ASSETS			
Debtors: amounts falling due after more than one year	10	<u>4,594,517</u>	<u>141,584</u>
NET CURRENT ASSETS		<u>4,594,517</u>	<u>141,584</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u><u>5,594,582</u></u>	<u><u>5,594,582</u></u>
CAPITAL AND RESERVES			
Called up share capital	11	1	1
Other reserves	12	6,724,207	6,724,207
Retained earnings	12	<u>(1,129,626)</u>	<u>(1,129,626)</u>
SHAREHOLDERS' FUNDS		<u><u>5,594,582</u></u>	<u><u>5,594,582</u></u>

10-Dec-2020

The financial statements were approved by the director on and were signed by:

DocuSigned by:



532054688D1D422.....

A Reed - Director

Catalent U.K. Swindon Holding II Limited (Registered number: 04146962)**Statement of Changes in Equity**
for the Year Ended 30 June 2020

	Called up share capital £	Retained earnings £	Other reserves £	Total equity £
Balance at 1 July 2018	1	(1,129,626)	6,724,207	5,594,582
Result for the year	-	-	-	-
Other comprehensive income/(loss) for the year	-	-	-	-
Total comprehensive income/(loss) for the year	-	-	-	-
Balance at 30 June 2019	<u>1</u>	<u>(1,129,626)</u>	<u>6,724,207</u>	<u>5,594,582</u>
Result for the year	-	-	-	-
Other comprehensive income/(loss) for the year	-	-	-	-
Total comprehensive income/(loss) for the year	-	-	-	-
Balance at 30 June 2020	<u>1</u>	<u>(1,129,626)</u>	<u>6,724,207</u>	<u>5,594,582</u>

Catalent U.K. Swindon Holding II Limited (Registered number: 04146962)

Notes to the Financial Statements
for the Year Ended 30 June 2020

1. STATEMENT OF COMPLIANCE

Catalent U.K. Swindon Holding II Limited is a limited liability company incorporated in England. The Registered Office is Frankland Road, Blagrove, Swindon, Wiltshire, SN5 8YG

The company's financial statements have been prepared in compliance with FRS 102 as it applies to the financial statements of the company for the year ended 30 June 2020. The financial statements were authorised for issue by the board of directors on 10 December 2020.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements have been prepared in accordance with applicable accounting standards. The financial statements are prepared in pound sterling which is the functional currency of the company and rounded to the nearest pound.

The financial statements present information about the company as an individual undertaking and not about its group. The company has taken advantage of the exemption from preparing consolidated accounts by virtue of section 401 of the Companies Act 2006, as it is a wholly owned subsidiary of Catalent Pharma Solutions Inc., for whom consolidated accounts are available to the public. See note 14 for details.

Going concern

The Company has limited activity and has limited cash flows outside of the Catalent Inc ("Catalent") group. The recoverability of its assets is dependent on the financial position of the Catalent group. The impact of COVID-19 (coronavirus) on global economic development is currently unpredictable, however Catalent has significant liquidity headroom as a result of the continued successful operational performance of the Group. The directors have viewed the going concern of the business for a period of at least 12 months from the approval date and having assessed the responses of the management of Catalent to their enquiries have no reason to believe that a material uncertainty exists that may cast significant doubt on the ability of the Catalent group to continue as a going concern. On the basis of their assessment of the company's financial position and relevant enquiries, the directors have a reasonable expectation that the company will be able to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the annual financial statements.

Financial reporting standard 102 - reduced disclosure exemptions

The company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

- the requirements of Section 7 Statement of Cash Flows.
- the requirements of Section 33 Related Party Disclosures.

Significant judgements and estimates

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported for assets and liabilities as at the balance sheet date and the amounts reported for revenues and expenses during the year. However, the nature of estimation means that actual outcomes could differ from those estimates. The following judgements (apart from those involving estimates) have had the most significant effect on amounts recognised in the financial statements.

Investments - Investments are stated at their historic cost to the company less, where appropriate, impairment provisions for any permanent or temporary diminution in value. The determination of the recoverable amount of an investment involves the use of estimates by management.

There are no significant estimates.

Fixed asset investments

Fixed asset investments are stated at cost less provisions for any diminution in value on a line by line basis.

Catalent U.K. Swindon Holding II Limited (Registered number: 04146962)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2020

2. ACCOUNTING POLICIES - continued

Financial instruments

The company has chosen to adopt the requirements of sections 11 and 12 of FRS102 in respect of the measurement and disclosure of financial instruments.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method, less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases, the receivables are stated at cost less impairment losses for bad and doubtful debts.

The company does not have any 'other' financial instruments.

Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the income statement because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on timing difference between carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible timing differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Current or deferred tax for the year is recognised in the income statement, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively.

3. STAFF COSTS

There were no staff costs for the year ended 30 June 2020 nor for the year ended 30 June 2019.

4. AUDITOR'S REMUNERATION

The company's audit fees were borne by Catalent U.K. Swindon Zydis Limited, a company within the wholly owned Catalent Pharma Solutions group.

5. DIRECTORS' EMOLUMENTS

The directors did not receive any remuneration from the company. The directors of the company received their remuneration from other group companies during the year. The directors of the company are also directors or officer of other companies within the Catalent Pharma Solutions group. The directors' services to the company do not occupy a significant amount of their time. As such the directors do not consider that they have received any remuneration for their incidental service to the company for the years ended 30 June 2020 and 30 June 2019.

Catalent U.K. Swindon Holding II Limited (Registered number: 04146962)**Notes to the Financial Statements - continued**
for the Year Ended 30 June 2020**6. INCOME FROM INVESTMENTS**

	2020	2019
	£	£
Dividend received from subsidiary undertaking	<u>4,494,854</u>	<u>-</u>

On 11 March 2020 the company received a dividend in specie of £4,494,854 from its subsidiary Catalent U.K. Swindon Encaps Limited. The subsidiary's net assets and liabilities were used to fulfil the dividend.

7. AMOUNTS WRITTEN OFF INVESTMENTS

	2020	2019
	£	£
Amounts written off investments (note 9)	<u>4,494,854</u>	<u>-</u>

8. TAXATION**Analysis of the tax charge**

No liability to UK corporation tax arose on ordinary activities for the year ended 30 June 2020 nor for the year ended 30 June 2019.

Factors that may affect future tax charges

The Finance Act 2016 was enacted on 15 September 2017 and announced a reduction in the main rate of corporation tax from 20% to 19% from 1 April 2017.

As the Company has no deferred tax assets or liabilities, there is no current impact due to the tax changes.

9. FIXED ASSET INVESTMENTS

	Shares in group undertakings £
COST	
At 1 July 2019	98,215,000
Investments written off	97,214,935
At 30 June 2020	<u>1,000,065</u>
PROVISIONS	
At 1 July 2019	92,762,002
Investments written off	(92,765,002)
At 30 June 2020	<u>-</u>
NET BOOK VALUE	
At 30 June 2020	<u>1,000,065</u>
At 30 June 2019	<u>5,452,998</u>

The investment write off recorded relates to the subsidiary Catalent U.K. Swindon Encaps Limited which has wound down its operations and is no longer trading. On 6 March 2020 a written resolution was passed for the dissolution of Catalent U.K. Swindon Encaps Limited and was approved by Companies House on 29 September 2020.

Catalent U.K. Swindon Holding II Limited (Registered number: 04146962)**Notes to the Financial Statements - continued**
for the Year Ended 30 June 2020**9. FIXED ASSET INVESTMENTS - continued**

Details of the investments in which the company holds 20% or more of the nominal value of the share capital are as follows:

Name of undertaking	Description of shares	Principal activity
Catalent U.K. Swindon Zydis Limited	Ordinary 50p	Development and commercialisation of the Zydis fast-dissolving dosage form.

Registered addresses

Catalent U.K. Swindon Zydis Limited - Capella Building (Tenth Floor), 60 York Street, Glasgow, G2 8JX

The company directly holds 100% of the nominal value of the issued share capital of the above.

10. DEBTORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

	2020	2019
	£	£
Amounts owed by group undertakings	<u>4,594,517</u>	<u>141,584</u>

The amount owed is non-interest bearing and unsecured. There are no set terms for repayment.

11. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:	Class:	Nominal value:	2020	2019
			£	£
1	Ordinary	£1	<u>1</u>	<u>1</u>

12. RESERVES

Retained earnings includes all current and prior period retained profits and losses.

A non-repayable and non-interest bearing capital contribution of £6,724,207 received from the immediate parent company is included within 'Other reserves'.

On 6 March 2020 a written resolution was passed for the dissolution of Catalent U.K. Swindon Encaps Limited and for the recommendation of a dividend on 11 March 2020 in specie in the sum of £4,494,854 to be distributed from Catalent U.K. Swindon Encaps Limited to Catalent UK Swindon Holding II Limited.

13. RELATED PARTY DISCLOSURES

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group. The balances held with related parties are presented in aggregate within note 8.

Catalent U.K. Swindon Holding II Limited (Registered number: 04146962)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2020

14. ULTIMATE PARENT COMPANY AND CONTROLLING PARTY

Catalent Pharma Solutions Limited is the immediate parent company.

Catalent Pharma Solutions Inc., a company incorporated in the USA, is the ultimate parent undertaking and ultimate controlling party, and heads the group in which the results of the company are consolidated. It is also the smallest group for which consolidated financial statements are publicly available. Copies of these group financial statements may be obtained from: Catalent Pharma Solutions Inc., 14 Schoolhouse Road, Somerset, NJ 08873, United States of America, or; investors@catalent.com.

Certificate Of Completion

Envelope Id: DFFE3A0A7934D339F8D11A59A565DEE

Status: Completed

Subject: Please DocuSign: 20 Catalent Swindon Holdings II - Final.pdf

Source Envelope:

Document Pages: 16

Signatures: 3

Envelope Originator:

Certificate Pages: 4

Initials: 0

Marshall, Becky

AutoNav: Enabled

14 Schoolhouse Rd

Enveloped Stamping: Enabled

Somerset, NJ 08873-1213

Time Zone: (UTC-05:00) Eastern Time (US & Canada)

Becky.Marshall@catalent.com

IP Address: 151.231.199.187

Record Tracking

Status: Original

Holder: Marshall, Becky

Location: DocuSign

12/10/2020 8:36:13 AM

Becky.Marshall@catalent.com

Signer Events

Signature

Timestamp

Alex Reed

Alex.Reed@catalent.com

Finance Director, Swindon

Security Level: Email, Account Authentication
(None)

DocuSigned by:

Alex Reed
532054886D1D422...

Signature Adoption: Pre-selected Style
Using IP Address: 165.225.197.136

Sent: 12/10/2020 8:37:42 AM

Viewed: 12/10/2020 8:56:27 AM

Signed: 12/10/2020 8:56:37 AM

Electronic Record and Signature Disclosure:

Accepted: 12/10/2020 8:56:27 AM

ID: d63a21fa-5c09-4369-961c-b1743edf6eb3

In Person Signer Events

Signature

Timestamp

Editor Delivery Events

Status

Timestamp

Agent Delivery Events

Status

Timestamp

Intermediary Delivery Events

Status

Timestamp

Certified Delivery Events

Status

Timestamp

Carbon Copy Events

Status

Timestamp

Witness Events

Signature

Timestamp

Notary Events

Signature

Timestamp

Envelope Summary Events

Status

Timestamps

Envelope Sent

Hashed/Encrypted

12/10/2020 8:37:42 AM

Certified Delivered

Security Checked

12/10/2020 8:56:27 AM

Signing Complete

Security Checked

12/10/2020 8:56:37 AM

Completed

Security Checked

12/10/2020 8:56:37 AM

Payment Events

Status

Timestamps

Electronic Record and Signature Disclosure

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Catalent Pharma Solutions, Inc. (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through your DocuSign, Inc. (DocuSign) Express user account. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to these terms and conditions, please confirm your agreement by clicking the 'I agree' button at the bottom of this document.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. For such copies, as long as you are an authorized user of the DocuSign system you will have the ability to download and print any documents we send to you through your DocuSign user account for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. To indicate to us that you are changing your mind, you must withdraw your consent using the DocuSign 'Withdraw Consent' form on the signing page of your DocuSign account. This will indicate to us that you have withdrawn your consent to receive required notices and disclosures electronically from us and you will no longer be able to use your DocuSign Express user account to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through your DocuSign user account all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Catalent Pharma Solutions, Inc.:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: Jean-Marc.Hubsch@catalent.com

To advise Catalent Pharma Solutions, Inc. of your new e-mail address

To let us know of a change in your e-mail address where we should send notices and disclosures electronically to you, you must send an email message to us at Jean-Marc.Hubsch@catalent.com and in the body of such request you must state: your previous e-mail address, your new e-mail address. We do not require any other information from you to change your email address..

In addition, you must notify DocuSign, Inc to arrange for your new email address to be reflected in your DocuSign account by following the process for changing e-mail in DocuSign.

To request paper copies from Catalent Pharma Solutions, Inc.

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an e-mail to Jean-Marc.Hubsch@catalent.com and in the body of such request you must state your e-mail address, full name, US Postal address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Catalent Pharma Solutions, Inc.

To inform us that you no longer want to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your DocuSign account, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an e-mail to Jean-Marc.Hubsch@catalent.com and in the body of such request you must state your e-mail, full name, US Postal Address, telephone number, and account number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

Operating Systems:	Windows2000? or WindowsXP?
Browsers (for SENDERS):	Internet Explorer 6.0? or above
Browsers (for SIGNERS):	Internet Explorer 6.0?, Mozilla FireFox 1.0, NetScape 7.2 (or above)
Email:	Access to a valid email account
Screen Resolution:	800 x 600 minimum
Enabled Security Settings:	<ul style="list-style-type: none">•Allow per session cookies•Users accessing the internet behind a Proxy Server must enable HTTP 1.1 settings via proxy connection

** These minimum requirements are subject to change. If these requirements change, we will provide you with an email message at the email address we have on file for you at that time providing you with the revised hardware and software requirements, at which time you will have the right to withdraw your consent.

Acknowledging your access and consent to receive materials electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please verify that you were able to read this electronic disclosure and that you also were able to print on paper or electronically save this page for your future reference and access or that you were able to e-mail this disclosure and consent to an address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format on the terms and conditions described above, please let us know by clicking the 'I agree' button below.

By checking the 'I Agree' box, I confirm that:

- I can access and read this Electronic CONSENT TO ELECTRONIC RECEIPT OF ELECTRONIC RECORD AND SIGNATURE DISCLOSURES document; and
- I can print on paper the disclosure or save or send the disclosure to a place where I can print it, for future reference and access; and
- Until or unless I notify Catalent Pharma Solutions, Inc. as described above, I consent to receive from exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to me by Catalent Pharma Solutions, Inc. during the course of my relationship with you.